Visualitza per autor "Curigliano, Giuseppe"
Ara mostrant els elements 1-12 d 12
-
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial
André, Thierry; Berton, Dominique; Curigliano, Giuseppe; Sabatier, Renaud; Tinker, Anna; OAKNIN, ANA (American Medical Association, 2023-11) -
Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology
Castelo-Branco, L.; Awada, Ahmad; Pentheroudakis, G.; Perez-Gracia, J. L.; Mateo Valderrama, Joaquim; Tabernero Caturla, Josep; Curigliano, Giuseppe (Elsevier, 2021-10) -
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies
Hollebecque, Antoine; Salvagni, Stefania; Plummer, Ruth; Niccoli, Patricia; Capdevila Castillon, Jaume; Curigliano, Giuseppe (Wiley, 2022-09-01) -
Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis
González-Martínez, Silvia; Pizarro, David; Pérez-Mies, Belén; Caniego-Casas, Tamara; Cortés Castan, Javier; Palacios, José; Curigliano, Giuseppe (MDPI, 2021-10-28) -
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
Cardoso, Fatima; Cortés Castan, Javier; Musolino, Antonio; Saura Manich, Cristina; Rugo, Hope; Curigliano, Giuseppe; Im, Seock-Ah (American Medical Association, 2021-04) -
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Pascual, Javier; Attard, Gerhardt; Bidard, François-Clement; De Mattos-Arruda, Leticia; Diehn, Maximilian; Seoane Suarez, Joan; Curigliano, Giuseppe (Elsevier, 2022-08) -
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology
Onesti, Concetta Elisa; Tagliamento, Marco; Harbeck, Nadia; Bartsch, Rupert; Wildiers, Hans; Cortés Castan, Javier; Curigliano, Giuseppe (American Society of Clinical Oncology, 2021-02-02) -
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers
Felip Font, Enriqueta; Morgensztern, Daniel; Trigo, José Manuel; Moreno, Victor; Curigliano, Giuseppe; Rutkowski, Piotr (Springer, 2022-04) -
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
Cardoso, Fatima; Cortés Castan, Javier; Musolino, Antonio; Escriva de Romaní Muñoz, Santiago Ignacio; Saura Manich, Cristina; Rugo, Hope; Curigliano, Giuseppe; Im, Seock-Ah (American Society of Clinical Oncology, 2023-01-10) -
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
Albanell, Joan; Pérez-García, José Manuel; Gil-Gil, Miguel J.; Ruiz Borrego, Manuel; Comerma Blesa, Laura; Bellet Ezquerra, Meritxell; Curigliano, Giuseppe (American Association for Cancer Research, 2023-01-04) -
Pralsetinib in patients with RET fusion–positive non-small-cell lung cancer: A plain language summary of the ARROW study
Griesinger, Frank; Baik, Christina; Tan, Daniel; Lee, Dae Ho; Curigliano, Giuseppe; Subbiah, Vivek; GARRALDA, Elena (Future Medicine, 2024-02) -
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
Griesinger, Frank; Thomas, M.; Baik, Christina; Tan, Daniel S. W.; Garralda Cabanas, Elena; Subbiah, Vivek; Curigliano, Giuseppe (Elsevier, 2022-11)